Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary

András Inotai; Zsolt Abonyi-Tóth; György Rokszin; Zoltán Vokó

doi:10.1016/j.vhri.2015.03.020

Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary

Value Health Reg Issues. 2015 Sep:7:1-8. doi: 10.1016/j.vhri.2015.03.020. Epub 2015 Apr 22.

Authors

András Inotai¹, Zsolt Abonyi-Tóth², György Rokszin³, Zoltán Vokó⁴

Affiliations

¹ Syreon Research Institute, Budapest, Hungary. Electronic address: andras.inotai@syreon.eu.
² RxTarget Statistical Agency, Szolnok, Hungary; Department of Biomathematics and Informatics, Szent István University, Budapest, Hungary.
³ RxTarget Statistical Agency, Szolnok, Hungary.
⁴ Syreon Research Institute, Budapest, Hungary; Faculty of Social Sciences, Department of Health Policy and Health Economics, Institute of Economics, Eötvös Loránd University (ELTE), Budapest, Hungary.

PMID: 29698146
DOI: 10.1016/j.vhri.2015.03.020

Abstract

Background: There is an increasing social debate on expenditures on the care of patients with malignant diseases, especially in Central Eastern European countries with limited health resources.

Objectives: The aim of this research was to estimate the epidemiological and quality measures and resource use indicators in Hungary in four malignant conditions (breast, colorectal, lung, and prostate cancer) from the National Health Insurance Fund (NHIF) database.

Methods: Survival and cost analyses were performed on the NHIF database. Patient records containing the International Classification of Diseases (ICD) codes C50 (breast cancer), C18-C20 (colorectal cancer), C33-C34 (lung cancer), and C61 (prostate cancer) were considered eligible. Inclusion criteria were at least two consecutive ICD codes between 2000 and 2012, with a minimum of 30-day difference, or one ICD code, followed by patient death within 60 days. A total of 428,860 social insurance numbers met inclusion criteria.

Results: The number of new cases was 6381 for breast cancer, 8457 for colorectal cancer, 8902 for lung cancer, and 3419 for prostate cancer. The probability of 5-year overall survival from the first diagnosis was 75.2%, 41.3%, 17.1%, and 62.1%, respectively. Median time from first diagnosis to treatment initiation was less than 1 month in all conditions except for lung cancer. The annual cost of treatment was €2585, €3165, €4157, and €2834, respectively. Cost figures were compared with hemophilia as benchmark (€8284).

Conclusions: The results indicated that the database of the Hungarian NHIF is suitable for real-world data analysis in the field of oncology and can support long-term evidence-based policymaking.

Keywords: breast cancer; colorectal cancer; cost; evidence-based policymaking; hemophilia; lung cancer; mortality; new cases; payer’s database; prostate cancer; survival; time to treatment.